{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Percentage of patients with an Overall Response. Overall Response Rate= Minor response (\\>25%-50% reduction in serum IgM from baseline) + Partial Response (\\>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (\\>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).","groups":[{"description":"\\-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.\n\nDasatinib: Oral Study Drug(s):\n\n* Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.\n* This will continue for up to 24 cycles.\n\nDasatinib: Oral, daily, dosing per protocol, once a day for cycle","id":"OG000","title":"Dasatinib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}